TABLE 2.
Ongoing Clinical Trials of Checkpoint Inhibitors in Brain Metastases
| Melanoma | ||
|---|---|---|
| Trial number | Phase | Interventions |
| NCT02858869 | I | Pembrolizumab ± SRS |
| NCT02716948 | I | SRS + nivolumab in newly diagnosed patients |
| NCT02097732 | II | Ipilimumab induction in patients receiving SRS |
| NCT02374242 | II | Nivolumab ± ipilimumab |
| NCT03728465 | II | Nivolumab + ipilimumab in patients with >4 symptomatic brain metastases |
| NCT03175432 | II | Bevacizumab + atezolizumab in untreated patients |
| NCT02460068 | II | Fotemustine vs fotemustine + ipilimumab or ipilimumab + nivolumab |
| NCT02681549 | II | Bevacizumab + pembrolizumab in untreated patients |
| NCT03563729 | II | Pembrolizumab or ipilimumab + nivolumab in patients in need of steroid treatment |
| NCT03340129 | II | Ipilimumab + nivolumab + salvage radiotherapy |
| Nonsmall cell lung cancer | ||
| NCT02858869 | I | Pembrolizumab ± SRS |
| NCT02681549 | II | Bevacizumab + pembrolizumab in untreated patients |
| NCT02978404 | II | Nivolumab + SRS |
| NCT03325166 | II | Pembrolizumab + MRI with ferumoxytol |
| NCT02696993 | I/II | Ipilimumab + SRS |
Ongoing prospective clinical trials looking at immunotherapy in melanoma and nonsmall cell lung cancer brain metastases. A number of trials are investigating the role of combining checkpoint inhibitors with stereotactic radiosurgery.